PubMedJournal of the College of Physicians and Surgeons--Pakistan : JCPSP2026-09-05
Decades of Dengue in Pakistan: Is It Finally Time for a Vaccine?
Rai Versha Rani VR
Null.
PMID 42698261
Read full article →Drug Database
RA
rabies vaccine (Thrabis)
✓ ApprovedCadila Pharmaceuticals Ltd. · Recombinant Proteins · Recombinant Proteins
What is rabies vaccine?
rabies vaccine is a recombinant proteins developed by Cadila Pharmaceuticals Ltd.. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.
Drug Profile
| Brand Names | Thrabis |
| Company | Cadila Pharmaceuticals Ltd. |
| Drug Class | Recombinant Proteins, Vaccine |
| Route | Injectable (Others), Intramuscular (IM) Injection |
| Status | Approved |
Therapeutic Indications
rabies vaccine is developed for 1 unique indication across 1 therapeutic area.
| Therapeutic Area | Condition | Phase |
|---|---|---|
| Infections and infestations | Rabies | ✓ Approved |
Related Research Articles
PubMedAllergy and asthma proceedings2026-09-05
Effective media communication in allergy and immunology: A practical framework for pediatric advocacy.
Berger William E WE
Background: Effective communication between physicians and the public has become increasingly important in the modern media environment. Pediatricians and allergist/immunologists play a critical role in shaping public understanding of conditions such as food allergy, asthma, and vaccine safety. Objective: The objective was to provide a practical framework for clinicians to engage effectively with media, improve public health messaging, and enhance patient outcomes through clear, accurate, and impactful communication. Methods: This was a narrative review of literature that integrates health communication, media engagement, pediatric advocacy, allergy and immunology, public health messaging, vaccine communication, and asthma and food allergy education. Results: Successful media engagement requires preparation, audience awareness, message clarity, and strategic delivery. Core principles include simplifying complex medical information; maintaining credibility; and focusing on key public health messages, such as early food introduction, asthma control, and vaccine safety. The RATIO framework (Research, Audience, Targeted Topic, Interview Redirecting, Optimism) provides a structured approach to media advocacy. Conclusion: Physician engagement with media is an essential extension of clinical care. Effective communication can improve public understanding, counter misinformation, promote evidence-based health behaviors, and substantially affect adherence and preventive behaviors, particularly in vaccination and chronic disease management, particularly in pediatric populations.
PMID 42698176
Read full article →PubMedPneumonia (Nathan Qld.)2026-09-05
Healthcare resource utilization and cost of invasive pneumococcal disease, pneumonia, and acute otitis media in commercially and medicaid-insured children by risk group in the United States, 2018 to 2023.
Mohanty Salini S, Done Nicolae N, Song Yan Y, Wang Travis T et al.
Pneumococcal disease (PD) is a leading cause of morbidity among US children, particularly those with chronic medical conditions (CMC) and immunocompromising conditions (IC), and the decline in PD incidence was less pronounced in the late pneumococcal conjugate vaccine (PCV) 13 period. This study quantified healthcare resource utilization (HCRU) and costs among commercially and Medicaid-insured children with PD. This retrospective observational cohort study used Merative™ MarketScan® Commercial Database and Multi-State Medicaid Databases to identify children with invasive pneumococcal disease (IPD), all-cause pneumonia (ACP), and acute otitis media (AOM) episodes using inpatient and outpatient claims. HCRU and costs per PD episode were assessed in the commercially and Medicaid-insured populations, stratified by age (<2, 2-4, and 5-17 years) and risk group (CMC, IC, and no CMC/IC). Between 2018 and 2023, commercially insured children contributed 23.6 million person-years (PY) and Medicaid-insured children contributed 23.4 million PY; 423 and 664 children had IPD, 309,540 and 281,569 had ACP, and 2,721,354 and 2,596,201 had AOM in the commercial and Medicaid populations, respectively. In both databases, HCRU and cost was higher in children with CMC or IC, compared to no CMC/IC across age groups for all PD manifestations. For IPD and ACP, inpatient admissions were 1.4 to 2.2-fold longer for children with CMC or IC. For IPD, costs per episode were 2-to-3-fold higher in children with CMC or IC, compared with those without CMC/IC (Commercial: $76,278 and $72,130 vs. $22,371; Medicaid: $17,389 and $19,945 vs. $6,476, respectively). For ACP, costs were highest in children with IC, followed by CMC and no CMC/IC (Commercial: $7,343, $2,637, and $809; Medicaid: $3,257, $1,160, and $356, respectively). AOM showed a similar pattern, with highest costs in children with IC (Commercial: $608; Medicaid: $178), followed by CMC ($442; $141), and lowest in those without CMC/IC ($368; $123). US children with underlying conditions that increase susceptibility to PD experience substantially higher HCRU and costs compared with those without such conditions, across all PD manifestations, regardless of insurance type and age group. These findings underscore the need for risk-based prevention strategies, including vaccination, beyond early childhood in high-risk pediatric populations.
PMID 42698104
Read full article →PubMedThe Milbank quarterly2026-09-04
Vaccine Policy: The State Role in a Time of Public Health Disruption.
Rosenbaum Sara S
Policy Points Over the past year, the nation's highest-ranking public health officials have pursued a concerted strategy of degrading access to childhood vaccines and undermining public confidence in vaccine safety and efficacy. As primary regulators of medical care, states have the power to maintain strong public health protections. A strong childhood vaccination policy has three components: maintaining a robust routine childhood vaccination schedule; focusing on broad vaccine access; and restoring public confidence in the safety and efficacy of childhood immunization. Beginning in 2025, longstanding opponents of vaccines have held the highest positions of federal public health policy powers. Using these powers, high ranking officials have sought to disrupt vaccine coverage and delivery and sow public mistrust in vaccine safety and efficacy. The results of their efforts have been confusion and declining levels of childhood immunization. As of summer 2026, a federal court has enjoined efforts to degrade the childhood vaccine schedule and the public health expertise of the Advisory Committee on Immunization Practices, whose recommendations lie at the heart of US vaccine policy. As the nation's most important regulators of public health practice, states play a critical role in countering these efforts and protecting vaccine accessibility and acceptance.
PMID 42693907
Read full article →PubMedHealth science reports2026-09-04
HPV Vaccine Uptake, Hesitancy and Information Sources Among Young Adults: A Cross-Sectional Study of Korea and the US.
Jo Soojung S, Xu Dongjuan D, Song Hwanseok H
Despite the high effectiveness of HPV vaccination, uptake among young adults remains suboptimal. Healthcare policies, vaccine hesitancy, and sources of vaccine information may contribute to differences in vaccination behaviors across countries. To examine cross-national and sex-specific differences in HPV vaccine uptake and hesitancy among undergraduates in the US and Korea, and investigate the role of information sources. This cross-sectional study targeted undergraduate students in the US and Korea aged between 18 and 25. Data was collected from August 29, 2023, to February 20, 2024 using an online survey through social media exclusive to college students (Korea) and a university listserv (US). A total of 224 survey responses were analyzed after removing missing data (n = 43). HPV vaccine hesitancy, uptake, and frequency of information source use were assessed. HPV vaccine uptake was substantially higher in the US than in Korea (74.0% vs. 33.1%), with a significant sex gap observed only in Korea. Although no significant cross-national differences in HPV vaccine hesitancy were observed, sex-specific patterns emerged within each country (OR = 5.3; 95% CI = 1.1-25.3; p = 0.035). In the US, females reported slightly higher hesitancy than males, whereas in Korea, males reported greater hesitancy than females. In multivariable logistic regression, frequent use of social media was associated with higher odds of HPV vaccine hesitancy (OR = 3.3, 95% CI = 1.0-10.4, p = 0.043), while frequent use of professional organizations as an information source was associated with lower odds of hesitancy (OR = 0.4, 95% CI = 0.2-0.9, p = 0.024). Tailored public health strategies that address social media's potential role in shaping HPV vaccine hesitancy, while expanded policy support in Korea could improve uptake and reduce hesitancy.
PMID 42694360
Read full article →PubMedNature reviews. Rheumatology2026-09-04
Vaccination considerations in autoimmune rheumatic diseases.
Kapetanovic Meliha C MC
Patients with autoimmune rheumatic diseases (ARDs) are at increased risk of numerous vaccine-preventable infections owing to a combination of disease-related immune dysregulation, immunosuppressive therapies - including glucocorticoids - and comorbidities. Age-related immunosenescence further increases this susceptibility in older patients. The SARS-CoV-2 (COVID-19) pandemic and measles outbreaks have underscored the importance of optimizing vaccination strategies and improving adherence to recommendations. Nevertheless, coverage for routinely recommended vaccines, including influenza and pneumococcal vaccines, remains suboptimal in this population. Vaccine hesitancy is an important barrier driven by concerns regarding safety, tolerability, disease flares and the potential induction of new autoimmune phenomena. Advanced therapies - including B cell-depleting agents, chimeric antigen receptor T cell therapy and bispecific T cell engagers - can substantially impair vaccine-induced immune responses, highlighting the importance of optimizing vaccination timing in relation to treatment. Although most studies focus on humoral and cellular immune responses, evidence on the long-term durability of vaccine-induced immunity, the need for booster doses and real-world vaccine effectiveness in patients with ARDs remains limited. Ethical considerations are important. Although vaccination in adults is generally not mandatory, improving vaccine uptake reduces the burden of infections in patients with ARDs, contributes to herd immunity and provides indirect protection for other vulnerable populations.
PMID 42693283
Read full article →+9996 more articles available with a free account
Sign up free to view all articles →